apellis pharmaceuticals stock

At the very opening of the session, the stock price was $43.04 and reached a high price of $48.24, prior to closing the session it reached the value of $42.08. Guidance for Managing Ethical Issues in Infectious Disease ... Apellis Pharmaceuticals Inc. (NASDAQ:APLS) trade information. Get the latest Apellis Pharmaceuticals Inc (APLS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Market Cap. Volume today is less active than usual. Registration on or use of this site constitutes acceptance of our Terms of Service and Privacy Policy. View real-time stock prices and stock quotes for a full financial overview. J.P. Morgan Securi, AquaBounty Technologies, Inc. Participation from Market Makers and ECNs is strictly voluntary and as a result, these sessions may offer less liquidity and inferior prices. The stock touched a low price of $42.72.Recen So far 321,496 shares have traded compared to average volume of 2,512,233 shares. Revenue) or per share (e.g. The contributors to this book offer inside views of this seminal industry, with historical and personal perspectives, lessons learned, and looks into the future. This book discusses the most basic as well advanced issues on biological products for successfully managing a life sciences industry. Find real-time APLS - Apellis Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN Business. Apellis Pharmaceuticals stock plunges after disappointing result from GA treatment studies MarketWatch. The second section of Ophthalmic Microsurgery addresses the specific applications. While not an encyclopedia of all surgical interventions, Drs. • Significant research and increase in knowledge about retinal diseases in recent years • Highly practical and clinically relevant • All editors with international reputation and contributing authors with expertise on their topic • ... Shares of Apellis Pharmaceuticals ( NASDAQ:APLS), a biopharmaceutical company focused on rare diseases, are sliding lower on Friday. During the day the stock fluctuated 4.66% from a day low at $44.87 to a day high of $46.96. News Apellis Pharmaceuticals Inc.APLS. Considering analysts have assigned the stock a price target range of $28.00-$116.00 as the low and high respectively, we find the trailing 12-month average consensus price target to be $68.69. Apellis Pharmaceuticals Inc. (NASDAQ:APLS) price on Friday, October 08, fall -1.07% below its previous day's close as a downside momentum from buyers pushed the stock's value to $33.19. This suggests a possible upside of 61.1% from the stock's current price. Over the last decade, the volume of research into the pathophysiology and genetics of pulmonary diseases has increased greatly. Description : Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Accessibility Statement | When autocomplete results are available use up and down arrows to review and enter to select. The stock's lowest day price was 32.74. Data Provided by Refinitiv. Enabling power: European Union (Withdrawal) Act 2018, s. 8 (1). Reading this book is the only way to have a specific strategy. This book offers you a chance to trade APLS Stock at predicted prices. Eight methods for buying and selling APLS Stock at predicted low/high prices are introduced. Dr. Deschatelets owns 875,837 shares of Apellis Pharmaceuticals stock worth more than $37,012,872 as of November 18th. APELLIS PHARMACEUTICALS, INC. October 21, 2021 2:44 PM EDT. Complete Apellis Pharmaceuticals Inc. stock information by Barron's. View real-time APLS stock price and news, along with industry-best analysis. Get a full understanding of how Apellis Pharmaceuticals, Inc. is performing with stock quotes and prices, as well as real . Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is focused on developing novel therapeutic compounds to treat disease through the inhibition of the complement system. The Apellis Pharmaceuticals Inc. stock price fell by -4.22% on the last day (Wednesday, 17th Nov 2021) from $47.11 to $45.12. Apellis Pharmaceuticals stock was originally listed at a price of $14.03 in Nov 9, 2017. Apellis Pharmaceuticals reported mixed results for an eye-disease treatment, leading APLS stock to crash on Friday.. X. "Financial Freedom Rx is a book directed toward physicians and their unique financial situation. This book provides specific guidance on where you should put your next dollar depending on where you are financially in life. Stock Chart. Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. 13 analysts have issued 1 year target prices for Apellis Pharmaceuticals' shares. The estimated net worth of Pascal Deschatelets is at least $37.01 million as of June 24th, 2021. The price has been going up and down for this period, and there has been a 31.01% gain for the last 2 weeks. Market Cap (Capitalization) is a measure of the estimated value of the common equity securities of the company or their equivalent. This set off a volatile share price that had its ups and downs throughout the year. The price has been going up and down for this period, and there has been a 31.01% gain for the last 2 weeks. Apellis Pharmaceuticals' stock options are financial instruments that give investors the right to buy or sell shares of Apellis Pharmaceuticals common stock at a specified price for a given time period. Get the latest Apellis Pharmaceuticals APLS detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. Register for your free account today at data.nasdaq.com. When we look at Apellis Pharmaceuticals Inc.'s average trading volume, we note the 10-day average is 1.78 million shares, with the 3-month average coming to 1.71 million. WALTHAM, Mass., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,312,500 shares at the public offering . */ This compares to loss of $1.79 per share a year ago. It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. Apellis Pharmaceuticals, Inc. (APLS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? This net worth approximation does not reflect any other assets that Dr. Deschatelets may own. Do NOT follow this link! Zacks - Mon Oct 25, 2:01PM CDT . Get prepared with the key expectations. Learn More. balance sheet and inputs from the stock market. Apellis Pharmaceuticals Inc (APLS) stock is trading at $45.45 as of 2:31 PM on Wednesday, Nov 17, a drop of -$1.66, or -3.52% from the previous closing price of $47.11. Press Release reported on 10/15/21 that Aspaveli(R) (pegcetacoplan) r These symbols will be available throughout the site during your session. Apellis Pharmaceuticals downgraded to neutral from outperform at Wedbush MarketWatch. These 11 analysts have an average price target of $69.36 versus the current price of Apellis Pharmaceuticals at 29.975, implying upside. ET). On average, they anticipate Apellis Pharmaceuticals' stock price to reach $74.00 in the next year. * Average Estimates in Million (e.g. WALTHAM, Mass., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,312,500 shares at the public offering price of $40.00 per share. A high-level overview of Apellis Pharmaceuticals, Inc. (APLS) stock. Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is not the most popular stock in this group but hedge fund interest is still above average. Apellis stock price target cut to $57 from $101 at J.P. Morgan MarketWatch. The pharmaceutical industry is burgeoning, owing to substantial investments and research breakthroughs and advances. #block-survival { display: none;} .okta_icons_box:nth-child(3) { display: none;} .social-container .okta_icons_box:nth-child(3) { display: none;} .c-feature-card--video .nsdq_video__created,.c-feature-card__header .nsdq_video__description { display: none; } The exercise of the option to purchase additional shares brought the total number. WALTHAM, Mass., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today announced the closing of its . The second edition includes new chapters on payer value story development, oncology, orphan drugs and payer negotiations. APLS - Stock quote for APELLIS PHARMACEUTICALS, INC. - MSN Money. The first comprehensive review of the use of optical coherence tomography in neurological diseases for neurologists, neuro-ophthalmologists, and neuroradiologists. In a report issued on September 10, Needham also assigned a Buy rating to the stock with a $70.00 price target. There are 76.67% institutions holding the Apellis Pharmaceuticals Inc. stock share, with Wellington Management Group, LLP the top institutional holder. [CDATA[/* >